RDIF与Landsteiner Scientific Ink签署了向墨西哥提供Sputnik V COVID-19疫苗的协议
发表于09/10/2020
于2020年9月9日发布，
俄罗斯直接投资基金（RDIF）的Landsteiner Scientific制药公司宣布了一项协议，将向墨西哥提供3200万剂俄罗斯Sputnik V疫苗。
这大约相当于墨西哥人口的25％。
RDIF：
该公司称，交付工作预计将在2020年11月开始，但要获得墨西哥监管机构的批准。
Landsteiner Scientific：
成立于1998年，是一家垂直整合的私有制药公司，总部位于墨西哥城。
According to the press release,
“As part of the agreement with RDIF, Landsteiner Scientific as a partner of RDIF would distribute the vaccine in Mexico.
On August 11,
the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiologywas registered by the Ministry of Health of Russia and became the world’s first registered vaccine against COVID-19 based on human adenoviral vectors platform.
Detailed information on the Sputnik V vaccine, the technological platform of human adenoviral vectors, and other details are available at sputnikvaccine.comOn September 4, a research paper on the results of Phase I and Phase II clinical trials of the Sputnik V vaccine
was published in one of the leading international medical journals The Lancet.
Phase I and Phase II trials :
demonstrated no serious adverse events and a stable immune response in 100% of participants.
Post-registration clinical trials of Sputnik V vaccine involving 40,000 volunteers are currently ongoing.First results of these trials :
are expected to be published in October-November 2020.
Health safety of the human adenovirus vaccines :
has been proven by more than 75 international publications and 250 clinical trials showing greater safety track record of human adenoviral vectors versus novel unproven technologies such as monkey adenoviral vectors or mRNA.”
SWFI
RDIF and Landsteiner Scientific agree to supply 32 million doses of Sputnik V vaccine to Mexico